User profiles for Jill Fulcher
Jill FulcherAssistant Professor of Medicine, University of Ottawa and Ottawa Hospital Research Institute Verified email at toh.ca Cited by 663 |
Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and …
Leukemia-initiating cells localize to bone marrow niches via cell surface CXCR4 binding to
stromal-derived factor 1 (SDF-1). Plerixafor, a CXCR4 antagonist, can mobilize and sensitize …
stromal-derived factor 1 (SDF-1). Plerixafor, a CXCR4 antagonist, can mobilize and sensitize …
[HTML][HTML] Consensus recommendations for MRD testing in adult B-cell acute lymphoblastic leukemia in Ontario
Measurable (minimal) residual disease (MRD) is an established, key prognostic factor in
adult B-cell acute lymphoblastic leukemia (B-ALL), and testing for MRD is known to be an …
adult B-cell acute lymphoblastic leukemia (B-ALL), and testing for MRD is known to be an …
Autologous hematopoietic stem cell transplantation for liver transplant recipients with recurrent primary sclerosing cholangitis: a pilot study
…, S Altouri, I Bence-Bruckler, M Cattral, J Fulcher… - …, 2022 - journals.lww.com
Background. Primary sclerosing cholangitis (PSC) is an indication for liver transplantation,
but recurrence after liver transplantation is associated with poor outcomes often requiring …
but recurrence after liver transplantation is associated with poor outcomes often requiring …
Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary …
T-Acute lymphoblast leukemia (T-ALL) accounts for 25-30% of adult ALL and occurs more
frequently in young adults. Up to 35% of adults with T-ALL have a high-risk subtype called …
frequently in young adults. Up to 35% of adults with T-ALL have a high-risk subtype called …
[HTML][HTML] Effect of donor age and donor relatedness on time to allogeneic hematopoietic cell transplantation in acute leukemia
…, H Atkins, L Huebsch, S Al-Touri, J Fulcher… - Biology of Blood and …, 2018 - Elsevier
Relapse after allogeneic hematopoietic cell transplantation (HCT) for acute leukemia can
be reduced when pursued early after first complete remission. The impact of donor age and …
be reduced when pursued early after first complete remission. The impact of donor age and …
[HTML][HTML] Primary Preventive Care of Hematopoietic Stem Cell Transplantation Survivors: Time to Educate and Empower Recipients and Providers
J Fulcher, AP Blanchard, C Bredeson… - … and Cellular Therapy, 2023 - Elsevier
Increasing use of hematopoietic stem cell transplantation (HCT) and improvements in recipient
outcomes have led to a steady increase in the number of allogeneic HCT survivors. In …
outcomes have led to a steady increase in the number of allogeneic HCT survivors. In …
[HTML][HTML] Predictive factors of overall survival and the completion of four cycles of azacitidine: an MDS-CAN study
…, K Rockwood, M Geddes, N Zhu, J Fulcher… - Blood, 2017 - Elsevier
In a real-world audit of azacitidine (AZA) in higher risk myelodysplasia (MDS) and oligoblastic
acute myeloid leukemia (AML) (Mozessohn et al. 2016), 410 of 1101 patients (33%) did …
acute myeloid leukemia (AML) (Mozessohn et al. 2016), 410 of 1101 patients (33%) did …
Total body irradiation (18 Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia
Outcomes of patients with refractory acute myeloid leukemia (rAML) are poor [1, 2]. Dose-intensification
of total body irradiation (TBI), reaching doses of 20Gy, with or without …
of total body irradiation (TBI), reaching doses of 20Gy, with or without …
[HTML][HTML] Health related quality of life remains stable over time in myelodysplastic syndrome: an MDS-CAN prospective study
…, M Lenis, L Chodirker, M Geddes, N Zhu, J Fulcher… - Blood, 2018 - Elsevier
Background: Health-Related Quality of life (HRQoL) is diminished in patients with myelodysplastic
syndrome (MDS). We have previously shown that HRQoL remains stable over time …
syndrome (MDS). We have previously shown that HRQoL remains stable over time …
Primary care for recipients of allogeneic hematopoietic stem cell transplantation
J Fulcher, S Hertz, C Bredeson - CMAJ, 2020 - Can Med Assoc
At 3 years after hematopoietic stem cell transplant (SCT), the probability of survival is 30%–60%,
with disease recurrence accounting for 50%–60% of deaths. 1 Cardiovascular disease (…
with disease recurrence accounting for 50%–60% of deaths. 1 Cardiovascular disease (…